Akashi Therapeutics Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • Series A1
  • Latest Deal Amount
  • $1.5M
Latest Deal Amount
  • Investors
  • 3

Akashi Therapeutics General Information

Description

Operator of a clinical stage biopharmaceutical company intended to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. The company's treatments promote healthy muscle regeneration and builds muscle mass and strength, enabling patients to transform their situations from a fatal, aggressive muscle-wasting disease to a chronic, manageable condition.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 245 First Street
  • 18th Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Akashi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A1) 03-Jul-2014 $1.5M 00.00 00.00 Completed Generating Revenue
2. Grant 000 000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Apr-2013 $6M $6M 0000 Completed Generating Revenue
To view Akashi Therapeutics’s complete valuation and funding history, request access »

Akashi Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 000,000 00.000000 00.0 000 000 00 000 00.000
To view Akashi Therapeutics’s complete cap table history, request access »

Akashi Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Benjamin Seckler MD Co-Founder
Bahaa Fam Advisor
Ernest Bush Ph.D Chief Scientific Officer
John Dyett Advisor
You’re viewing 4 of 9 executive team members. Get the full list »

Akashi Therapeutics Board Members (3)

Name Representing Role Since
Tracy Seckler Charley's Fund Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Akashi Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akashi Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MDA Venture Philanthropy Venture Capital Minority 000 0000 000000 0
Charley's Fund Not-For-Profit Venture Capital 000 0000 000000 0
Nash Avery Foundation Other 000 0000 000000 0
To view Akashi Therapeutics’s complete investors history, request access »

Akashi Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 15-Sep-2014 000000000000000000 Drug Discovery 0000 000000000
Collgard Biopharmaceuticals 01-Mar-2011 Merger/Acquisition 000 Therapeutic Devices
To view Akashi Therapeutics’s complete acquisitions history, request access »

Akashi Therapeutics Subsidiaries (1)

Company Name Industry Location Founded
00000 000000000000 Drug Discovery Williamsville, NY 0000
To view Akashi Therapeutics’s complete subsidiaries history, request access »